Every material Form 8-K Edgewise Therapeutics, Inc. has filed with the SEC since July 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edgewise Therapeutics reported third quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, compared with a net loss of $40.7 million in the same period of 2025. The swing reflects a $1.348 billion gain on the July 2026 sale of the sevasemten program and muscular dystrophy business to Servier, while operating expenses were roughly flat year over year.
Net income of $1,166.2 million ($9.65 per diluted share) versus a net loss of $40.7 million ($0.39 per share) in Q3 2025
Gain on the sevasemten sale to Servier was $1.348 billion; the company received $1.396 billion in upfront cash at closing
Research and development expenses were $31.6 million versus $37.5 million; general and administrative expenses rose to $14.6 million from $9.4 million
Cash, cash equivalents and marketable securities were $1,743.9 million as of September 30, 2026
Edgewise Therapeutics reported a second-quarter 2026 net loss of $57.3 million, or $0.53 per share, up from $36.1 million, or $0.34 per share, a year earlier, as research and development and general and administrative costs rose. The company completed the sale of sevasemten and its muscular dystrophy business to Servier on July 10, 2026, for $1.55 billion in upfront cash, which the company says leaves it with a pro forma balance of $2,010.7 million before taxes and transaction costs, versus $460.7 million at June 30, 2026.
Net loss of $57.3 million ($0.53 per share) for Q2 2026, compared with $36.1 million ($0.34 per share) for Q2 2025
R&D expenses rose to $47.5 million from $33.6 million; G&A expenses rose to $14.4 million from $9.1 million
Cash, cash equivalents and marketable securities were $460.7 million at June 30, 2026; pro forma balance of $2,010.7 million including $1,550.0 million upfront sale proceeds
Company expects to start a Phase 3 CIRRUS-HCM trial of EDG-7500 in Q4 2026
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier on July 10, 2026, receiving $1.55 billion in upfront cash plus up to $1.1 billion in additional milestone payments. The company says the proceeds strengthen its balance sheet and will fully fund development of its cardiovascular pipeline, led by EDG-7500, through potential approval.
Upfront cash consideration of $1.55 billion; milestone payments of up to $1.1 billion, for aggregate potential consideration of up to $2.65 billion.
Transaction completed July 10, 2026; Edgewise announced completion in a press release dated July 13, 2026.
Edgewise expects to start a Phase 3 trial of EDG-7500 in the fourth quarter of 2026 and a Phase 2 trial of EDG-15400 in HFpEF.
Edgewise intends to file pro forma financial information in a Form 8-K/A no later than four business days after completion.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edgewise Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →